ERBB2 and metastatic neoplasm: Though targeted therapies are efficacious in non-advanced disease, a reported 20–50% of HER2+ metastatic tumors have an inherent resistance to trastuzumab or other HER2-targeted agents, and 10–15% will acquire resistance within the first year of treatment [10,19,20].